Respiratory Disease Testing Is Estimated To Witness High Growth Owing To Rising Prevalence Of Respiratory Diseases
![]() |
Respiratory Disease |
The Respiratory Disease Testing Market is estimated to be valued at US$ 3,232 Mn in 2023 and is expected to exhibit a CAGR of 4.0% over the forecast period
2023 to 2030, as highlighted in a new report published by Coherent Market
Insights.
Market Overview:
The respiratory disease testing market covers testing solutions for various
respiratory diseases such as asthma, chronic obstructive pulmonary disease
(COPD), lung cancer, and various other respiratory infections. The testing
includes imaging tests, respiratory measurement tests, blood gas tests, and
other molecular diagnostic tests. These tests aid in early detection and
diagnosis of respiratory diseases, enabling timely treatment interventions.
The respiratory disease testing market is driven by the rising prevalence
of respiratory diseases globally. As per the Centers for Disease Control and
Prevention (CDC), in 2017, around 25 million adults and 8 million children in
the U.S. suffered from asthma alone. Moreover, various environmental factors
such as rising air pollution levels and toxic fumes are contributing to the
development of respiratory diseases, thereby increasing demand for advanced
respiratory testing solutions. Additionally, new product launches and expanding
applications of molecular diagnostics in respiratory disease testing are also
expected to aid market growth over the forecast period.
SWOT Analysis
Strength: Respiratory Disease Testing has
strong growth potential due to rising pollution levels and growing elderly
population globally. It provides non-invasive tests that help in early disease
detection. Many tests such as CT scans and pulmonary function tests can detect
over 20 diseases.
Weakness: High cost of specialized
equipment and tests limit widespread adoption. Dependency on skilled
technicians for performance and interpretation of diagnostic tests.
Opportunity: Untapped developing
markets and rising healthcare spending in Asia Pacific and Latin America
provide major growth opportunities. Growing adoption of home monitoring
solutions extend the reach of diagnostic tests.
Threats: Alternative diagnostic
methods and therapies pose competition. Stringent regulatory approvals and
reimbursement policies delay product adoption.
Key Takeaways
The Global Respiratory
Disease Testing Market Share is expected to witness high growth,
exhibiting CAGR of 4.0% over the forecast period, due to increasing burden of
respiratory diseases worldwide. Factors such as growing geriatric population,
rising pollution levels, and smoking prevalence are driving the need for early
diagnosis and treatment.
Regional analysis:
North America currently dominates the global market accounting for over 35%
share, led by availability of advanced healthcare facilities in the US and
Canada. However, Asia Pacific is projected to witness the fastest growth during
the forecast period, attributed to large patient pool, improving healthcare
infrastructure and rising medical tourism in China, India and Southeast Asian
countries.
Key players
Key players operating in the Respiratory Disease Testing market are CareFusion
Corporation, Carestream Health, Inc., COSMED, Futuremed America, Inc., GE
Healthcare, MGC Diagnostics Corporation, ndd Medical Technologies, Inc., Nihon
Kohden Corporation, Perkin Elmer, Inc., FUJIFILM Healthcare Corporation,
Philips Healthcare, Roche Healthcare, Beckton Dickinson and Company,
Koninklijke Philips N.V., ResMed Inc., Medtronic, Abbott Diagnostics, and Quest
Diagnostics. These players are focusing on new product launches, regional expansion
and mergers & acquisitions to gain major market share.
Comments
Post a Comment